AssetMemo

Disease

Breast Cancer

Breast Cancer clinical programs

Coverage in progress. AssetMemo has not yet run its full census for HER2-Positive Breast Cancer, Breast Cancer, so the assets listed for them are not complete.

Combined attributable cost

$22.7B+

Drug spend

$2.4B+

How this is calculated ↗

11% of total cost is drugs

Sum of 3 indications below.

Indications

HR+/HER2- Metastatic Breast Cancer
$22.7B attributable cost
$22,727/patient drugs
Metastatic (stage IV), de novo and recurrent · US
HER2-Positive Breast Cancer
Market size not yet sourced
All-stage · US
Breast Cancer
Market size not yet sourced
All-stage · US

All assets in Breast Cancer

← Oncology